Meanwhile, Sanket U. et al., reported that the use of IFNα2b (1 million IU/ml, 4 times/day for 6 months) as first line therapy for CIN, was related with complete tumor resolution in 19 of the 23 patients included. This evidence concerns the gene IFNA2 and neoplasm.